#81 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to understand that cannabis companies may not be adequately disclosing cannabinoid hyperemesis syndrome (CHS) risk to consumers, meaning patients may not recognize symptoms of this serious condition when they develop chronic nausea, vomiting, and abdominal pain. This litigation underscores the importance of clinicians proactively screening patients for cannabis use patterns and educating them about CHS risk, particularly those using high-potency products regularly. Healthcare providers should counsel patients that current marketing practices may downplay health risks, making independent clinical guidance essential for informed decision-making about cannabis use.
Federal litigation alleges that cannabis companies deliberately concealed information about cannabinoid hyperemesis syndrome (CHS), a serious condition characterized by cyclic nausea, vomiting, and abdominal pain that develops in some chronic users and can significantly impair quality of life. Recent 2025 research has further documented the association between long-term cannabis use and CHS development, strengthening evidence that manufacturers had access to relevant safety data. This lawsuit raises important questions about informed consent and the adequacy of product labeling and consumer warnings in an industry with limited FDA oversight and inconsistent regulatory standards across jurisdictions. Clinicians should be aware that patients presenting with unexplained cyclic vomiting, particularly those with heavy or prolonged cannabis use histories, may have unrecognized CHS and could benefit from targeted counseling about cessation or dose reduction. The case highlights the gap between clinical evidence and industry transparency, underscoring the need for clinicians to proactively discuss potential adverse effects with cannabis-using patients rather than relying solely on product information. Healthcare providers should document cannabis use patterns and educate patients about CHS risk as part of comprehensive substance use assessment, especially given the lack of manufacturer-provided warnings.
“When patients present with cyclic vomiting and abdominal pain that resolves only after they stop cannabis use, we’re looking at cannabinoid hyperemesis syndrome, and the industry’s failure to warn consumers about this risk represents a significant gap in informed consent that my patients deserve to know about before they develop a condition that can take months to diagnose.”
💊 Healthcare providers should be aware that cannabis companies face federal litigation for allegedly concealing known health risks, particularly cannabinoid hyperemesis syndrome (CHS), from consumers. While the causal mechanisms linking chronic cannabis use to CHS remain incompletely understood and individual susceptibility likely varies, the condition presents with severe cyclic vomiting, abdominal pain, and compulsive hot bathing—symptoms that may be misattributed to other gastrointestinal disorders if cannabis use history is not explicitly elicited. This legal action underscores a growing gap between emerging clinical evidence and marketing practices in an industry with limited regulatory oversight compared to pharmaceuticals. Clinicians should routinely ask patients about cannabis use patterns and frequency, maintain a low threshold for considering CHS in patients with unexplained recurrent vomiting, and counsel long-term users about potential risks, while acknowledging that evidence quality and population-level incidence remain areas
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
